A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma

Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.

开始日期2024-02-01

申办/合作机构

Memorial Sloan Kettering Cancer Center

NCT05108623 / Completed临床1期

A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agenT-797 in combination with approved immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid tumors.

开始日期2022-01-28

申办/合作机构

MiNK Therapeutics, Inc.

NCT04754100 / Completed临床1期

A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) in Subjects With Relapsed/Refractory Multiple Myeloma

开始日期2021-03-29

申办/合作机构

MiNK Therapeutics, Inc.

100 项与 AgenT-797 相关的临床结果

登录后查看更多信息

100 项与 AgenT-797 相关的转化医学

登录后查看更多信息

100 项与 AgenT-797 相关的专利（医药）

登录后查看更多信息

项与 AgenT-797 相关的文献（医药）

2024-09-18·Vaccines

Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs.

Article

作者: Krammer, Florian ; Touchard, Laurie ; Morozov, Igor ; Henningson, Jamie ; Artiaga, Bianca L ; Balaraman, Velmurugan ; Driver, John P ; Madden, Daniel ; Meade, Philip ; Richt, Juergen A ; McDowell, Chester ; Keating, Cassidy ; Kwon, Taeyong ; de Carvahlo Madrid, Darling Melany

Invariant natural killer T (iNKT) cells are glycolipid-reactive T cells with potent immunoregulatory properties. iNKT cells activated with the marine-sponge-derived glycolipid, α-galactosylceramide (αGC), provide a universal source of T-cell help that has shown considerable promise for a wide array of therapeutic applications. This includes harnessing iNKT-cell-mediated immune responses to adjuvant whole inactivated influenza virus (WIV) vaccines. An important concern with WIV vaccines is that under certain circumstances, they are capable of triggering vaccine-associated enhanced respiratory disease (VAERD). This immunopathological phenomenon can arise after immunization with an oil-in-water (OIW) adjuvanted WIV vaccine, followed by infection with a hemagglutinin and neuraminidase mismatched challenge virus. This elicits antibodies (Abs) that bind immunodominant epitopes in the HA2 region of the heterologous virus, which purportedly causes enhanced virus fusion activity to the host cell and increased infection. Here, we show that αGC can induce severe VAERD in pigs. However, instead of stimulating high concentrations of HA2 Abs, αGC elicits high concentrations of interferon (IFN)-γ-secreting cells both in the lungs and systemically. Additionally, we found that VAERD mediated by iNKT cells results in distinct cytokine profiles and altered adaptation of the challenge virus following infection compared to an OIW adjuvant. Overall, these results provide a cautionary note about considering the formulation of WIV vaccines with iNKT-cell agonists as a potential strategy to modulate antigen-specific immunity.

2024-08-01·VACCINE

Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity

Article

作者: Xian, Mao-Ying ; Yan, Cheng ; Hu, Xing ; Li, Ke ; Luo, Rui ; Li, Ya-Qian ; Liu, Zheng ; Zou, Guo-Qing

Protein-based subunit vaccines like RBD-Fc are promising tools to fight COVID-19. RBD-Fc fuses the receptor-binding domain (RBD) of the SARS-CoV-2 virus spike protein with the Fc region of human IgG1, making it more immunogenic than RBD alone. Earlier work showed that combining RBD-Fc with iNKT cell agonists as adjuvants improved neutralizing antibodies but did not sufficiently enhance T cell responses, a limitation RBD-Fc vaccines share with common adjuvants. Here we demonstrate that aluminum hydroxide combined with α-C-GC, a C-glycoside iNKT cell agonist, significantly improved the RBD-Fc vaccine's induction of RBD-specific T-cell responses. Additionally, aluminum hydroxide with α-GC-CPOEt, a phosphonate diester derivative, synergistically elicited more robust neutralizing antibodies. Remarkably, modifying αGC with phosphate (OPO₃H₂) or phosphonate (CPO₃H₂) to potentially enhance aluminum hydroxide interaction did not improve efficacy over unmodified αGC with aluminum hydroxide. These findings underscore the straightforward yet potent potential of this approach in advancing COVID-19 vaccine development and provide insights for iNKT cell-based immunotherapy.

2024-06-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists

Article

作者: Sun, Tiantian ; Xu, Ying ; Ding, Ning ; Yang, Jing ; Zong, Chengli ; Meng, Xiongyan ; Meng, Shuai

Covalently linking an adjuvant to an antigenic protein enhances its immunogenicity by ensuring a synergistic delivery to the immune system, fostering a more robust and targeted immune response. Most adjuvant-protein conjugate vaccines incorporate only one adjuvant due to the difficulties in its synthesis. However, there is a growing interest in developing vaccines with multiple adjuvants designed to elicit a more robust and targeted immune response by engaging different aspects of the immune system for complex diseases where traditional vaccines fall short. Here, we pioneer the synthesis of a dual-adjuvants protein conjugate Vaccine 1 by assembling a toll-like receptor 7/8 (TLR7/8) agonist, an invariant natural killer T cell (iNKT) agonist with a clickable bicyclononyne (BCN). The BCN group can bio-orthogonally react with azide-modified severe acute respiratory syndrome coronavirus-2 receptor-binding domain (SARS-CoV-2 RBD) trimer antigen to give the three-component Vaccine 1. Notably, with a mere 3 μg antigen, it elicited a balanced subclass of IgG titers and 20-fold more IgG2a than control vaccines, highlighting its potential for enhancing antibody-dependent cellular cytotoxicity. This strategy provides a practicable way to synthesize covalently linked dual immunostimulants. It expands the fully synthetic self-adjuvant protein vaccine that uses a single adjuvant to include two different types of adjuvants.

项与 AgenT-797 相关的新闻（医药）

2024-11-07

·GlobeNewswire-Health Care

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK’s iNKT cell therapy programs, agenT-797 and PRAME-TCR. “The data we presented at SITC reflect the potential of iNKT cell therapies to offer meaningful advancements in cancer treatment. AgenT-797 shows important immune modulating effects, enhancing the activity of immune checkpoint inhibitors and bispecific engagers,” said Dr. Marc Van Dijk, CSO at MiNK. “Additionally, our PRAME-TCR iNKT represents a novel and differentiated approach to treat PRAME positive solid tumors. By leveraging iNKT cells’ ability to target the tumor microenvironment without lymphodepletion or HLA-matching, we aim to provide durable, scalable, and accessible solutions for patients with limited treatment options.” AgenT-797 Combination Boosts Activity of Checkpoint Inhibitors and Bispecific Engagers in Challenging Solid Tumors AgenT-797 alone or in combination with anti-PD-1 (nivo or pembro) shows durable disease control in majority of heavily pretreated patients.AgenT-797 combined with bispecific engagers targeting antigens such as MUC16, HER2, Claudin 18.2, and DLL3, promote increased T-cell activation, efficient tumor cell killing, and reduced exhaustion and myeloid cell activity.Ongoing Clinical Studies: AgenT-797 is advancing in an enrolling Phase 2 trial with an innovative five-treatment combination regimen that includes botensilimab, balstilimab, and standard-of-care chemotherapy. This trial targets 2L+ advanced gastroesophageal cancer patients and is being conducted at Memorial Sloan-Kettering Cancer Center, with results expected in 2025. PRAME-TCR iNKT Represents a Promising Targeted Therapy for Refractory Solid Tumors iNKT cells present an ideal platform for tumor-targeting T cell receptor (TCR) expression due to the absence of conventional αβ TCRs and endogenous class I MHC molecules.MiNK’s allogeneic PRAME-targeted TCR addresses the limitations of traditional T cell therapies. As an allogeneic, gene-editing-free solution, it expresses an engineered αβ PRAME-TCR with no risk of heterodimerization, offering a potentially safer and more precise approach.In preclinical studies, PRAME-TCR-iNKTs direct tumor cell killing with high specificity, which highlights the versatility of iNKT cells and their potential of to treat solid tumors such as NSCLC, ovarian, melanoma and sarcoma. Presentation Details Title: AgenT-797 iNKT cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and bi-specific engagers to improve the anti-tumor response Abstract Number: 753 Date: Friday, November 8th Title: PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME Abstract Number: 374 Session Date: Saturday, November 9th About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact917-362-1370investor@minktherapeutics.com Media Contact781-674-4428communications@minktherapeutics.com

细胞疗法免疫疗法临床2期AACR会议

2024-10-08

·GlobeNewswire-Health Care

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, disease-activated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous’ precision encrypted RNA™ (encRNA) technology and MiNK’s innovative iNKT cell therapies, MiNK-215 and agenT-797. The companies will evaluate these technologies in state-of-the-art metastatic solid tumor models. The goal is to develop novel therapies that effectively target metastatic cancer cells in patients while avoiding healthy cells—a challenge that existing cancer medicines have not been able to overcome. Based on the results, the companies plan to launch a Phase 1 clinical trial in patients with treatment-refractory metastatic solid tumors, including microsatellite stable (MSS) colorectal cancers. “This collaboration underscores the unique potential of both native and engineered iNKT cells, allowing us to explore cutting-edge approaches that could significantly enhance clinical responses and deliver better outcomes for patients,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK. “MiNK-215 and agenT-797 are novel cell therapies designed to overcome the limitations of traditional immune checkpoint inhibitors. Recent preclinical models of MSS colorectal cancer with metastatic liver disease demonstrated that these iNKT cells have the potential to eliminate tumor cells effectively. By combining them with Autonomous Therapeutics' engineered RNA technology, we are confident that we can unlock even greater therapeutic possibilities and continue advancing our mission to transform the landscape of cell therapy.” Dr. Ariel Weinberger, Chief Executive Officer of Autonomous, added: “This exciting collaboration leverages the platform capabilities of our next-generation encrypted RNA technology and MiNK’s unique allogeneic cell therapy platform. AT313 is a preclinical encRNA candidate developed at Autonomous to enable the precision targeting of solid tumors, via cancer-activated therapeutic protein translation. Our aim is to develop novel medicines that pinpoint tumor cells in patients—by sensing and targeting the aberrant molecular signatures that define cancer replication. This would enable us to eliminate cancer cells in patients while sparing healthy and immune cells. It would also eliminate dose-limiting toxicities common to existing oncology medicines while significantly enhancing therapeutic efficacy—to dramatically improve Stage IV patient outcomes.” About MiNK-215 MiNK-215 is an investigational, off-the-shelf cellular immunotherapy, specifically designed to target immune resistance mechanisms and promote a potent anti-cancer immune response. Engineered to express CAR targeting the Fibroblast Activating Protein (FAP) protein prevalent in stromal cells within the tumor microenvironment, MiNK-215 also integrates soluble IL-15 for enhanced persistence (Michelet X et al, SITC 2022; Shan K et al, AACR 2023; Dijk MV et al, CICON 2023). In preclinical models resistant to immune checkpoint inhibitors, MiNK-215 has demonstrated remarkable efficacy, not only in eliminating tumor cells and FAP+ immune-suppressive cells but also facilitating the infiltration and persistence of proinflammatory cytotoxic T cells crucial for effective tumor elimination. About agenT-797 AgenT-797 is an investigational, off-the-shelf immune cell therapy product by MiNK Therapeutics, possessing anti-viral and immune-modulating properties. In a Phase 1 trial involving 54 patients with heavily pre-treated solid tumors, agenT-797 appears to overcome resistance to immune checkpoint inhibitors, with durable disease stabilization in multiple solid tumors and a confirmed response in chemotherapy and anti-PD-1 refractory gastric cancer (Carneiro et al, 2024 Oncogene). agenT-797 is being evaluated in an investigator sponsored Phase 2 trial in 2L gastric cancer, led by Dr. Yelena Janjigian, Chief of GI Oncology at Memorial Sloan-Kettering Cancer Center and supported by Stand Up to Cancer. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. About Autonomous Therapeutics, Inc. Autonomous Therapeutics is pioneering a new class of RNA medicines (encRNA) for difficult-to-treat indications in oncology and infectious disease. Autonomous has developed a proprietary pipeline of more than 10 encRNA candidates targeting indications from pandemic influenza to metastatic cancers. The company’s encRNA pipeline includes next-generation immunotherapies such as AT313, a cancer-activated RNA prodrug designed to precisely eliminate solid tumor cells. Autonomous’ partners and funders have included: the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health (NIH), the Office of the Secretary of Defense (OSD), Third Kind Venture Capital (3kVC), and BLUE KNIGHT™, a joint initiative between the Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation – JLABS. About encrypted RNA™ encRNA is a new class of RNA invented at Autonomous to enable the development of precision medicines against virtually any disease driven by aberrant nucleic acid expression or protein translation. Autonomous’ encRNA therapeutics leverage the molecular signatures of a targeted disease as intracellular logic gates—to drive precision therapeutic protein translation in targeted cells. Each encRNA candidate is designed to differentiate between healthy and diseased cells across a patient and to translate therapeutic proteins solely in diseased cells. encRNA candidates are modular and can be programmed with multiple logic gates for potential patient-specific sensitivity and specificity. In proof-of-concept studies, Autonomous has demonstrated the preclinical safety and efficacy of encRNA candidates in animal models, with the potential to completely eradicate immunologically “cold” solid tumors via precision immunotherapy. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. MiNK Investor Contact 917-362-1370 investor@minktherapeutics.com MiNK Media Contact 781-674-4428 communications@minktherapeutics.com

免疫疗法临床2期细胞疗法临床1期

2024-10-04

·GlobeNewswire-Health Care

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK’s iNKT cell programs, agenT-797 and PRAME-TCR. Presentation Details Title: AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response Abstract Number: 753 Date: Friday, November 8th Title: PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME Abstract Number: 374 Session Date: Saturday, November 9th About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com

细胞疗法免疫疗法

100 项与 AgenT-797 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
呼吸困难	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
流感病毒感染	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
成人呼吸窘迫综合征	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
严重急性呼吸综合征	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
自身免疫性疾病	临床2期	-	MiNK Therapeutics, Inc.	-
实体瘤	临床1期	美国	MiNK Therapeutics, Inc.	2022-01-28
移植物抗宿主病	临床1期	美国	MiNK Therapeutics, Inc.	2021-09-08
浆细胞骨髓瘤难治	临床1期	美国	MiNK Therapeutics, Inc.	2021-03-29
复发性多发性骨髓瘤	临床1期	美国	MiNK Therapeutics, Inc.	2021-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04582201 (Literature) 人工标引	临床1/2期	成人呼吸窘迫综合征	21	agenT-797	簾襯鏇鹽鏇糧積壓觸衊(鬱衊選鬱鏇遞願齋廠繭) = 醖積鏇鑰獵鬱選製簾鏇淵糧顧顧鏇鏇艱夢遞鑰 (築簾艱願衊製膚衊淵憲 )	积极	2024-02-06
NCT05108623 (Literature) 人工标引	临床1期	胃癌	1	AgenT-797	窪窪廠廠築膚壓艱膚醖(鏇窪選淵齋觸艱憲鹽選) = 齋齋顧遞願鹽範壓網鬱顧艱顧顧顧蓋範選觸壓 (簾廠鬱壓餘窪齋壓鹽網 )	积极	2024-01-29
AACR2023 人工标引	临床1期	晚期恶性实体瘤	32	agenT-797	鹽窪鹽膚憲艱齋鹽簾積(繭觸鹹積醖鬱壓餘襯簾) = 蓋顧構鏇鏇醖壓鏇齋鏇遞蓋繭顧糧鹽蓋範壓鑰 (製鑰鏇膚構顧襯艱廠觸 )	积极	2023-04-14
AACR2023 人工标引	临床1期	晚期恶性实体瘤	32	agenT-797+pembrolizumab or nivolumab	鏇膚醖廠窪顧憲襯鏇鏇(顧製鏇襯襯築觸憲齋製) = 艱遞窪鏇襯蓋廠廠艱觸衊觸廠簾艱鹽廠鹹壓鑰 (範壓顧餘簾淵觸繭觸糧 )	积极	2023-04-14
NCT04582201 (649, SITC2022)	临床1/2期	SARS-CoV-2 急性呼吸道疾病	20	AgenT-797 100 x 10^6 iNKT cells	蓋築積製鏇獵夢憲膚襯(艱願糧衊構艱範願簾衊) = Grade 4, possibly related to agenT-797 廠鹹範衊醖鬱獵遞鹽鑰 (壓繭顧壓蓋襯鑰壓鹹窪 ) 更多	积极	2022-11-07
NCT04582201 \| NCT04754100 (400, SITC2021)	N/A	呼吸困难 \| 新型冠状病毒感染 \| 复发性多发性骨髓瘤 ... 更多	-	Agent-797	鬱製鹽窪齋積獵製淵餘(夢衊繭衊積蓋鑰範鬱衊) = 構範積築鹽糧鏇淵簾襯繭選築壓醖繭醖網築糧 (鏇餘膚鹽鏇衊遞糧衊糧 )	积极	2021-11-10